

RECEIVED
CENTRAL FAX CENTER
AUG 21 2006


Reply Under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Docket No. 53001AUSM1

AMENDMENTS TO THE CLAIMS

The below listing of claims will replace all prior versions, and listings, of claims in the application.

1-10. (canceled)

11. (Previously Amended) A compound of formula (3a):



or an enantiomer, a diastereomer, a salt or a solvate thereof,

wherein:

R¹ is hydrogen or amino;

R² is halogen;

R³ is hydrogen, alkyl, halogenated alkyl, halogen, substituted or unsubstituted amino, nitro, cyano, or alkoxy;

R⁴ is hydrogen or one or more alkyl groups;

R^{1a} is oxo or thioxo;

R^{2a} and R^{3a} are independently hydrogen, oxo, or thioxo;

or, when bonded to adjacent ring carbon atoms, R^{2a} and R^{3a} may combine to form a fused aryl or heterocyclyl ring;

R²⁵ is

(i) hydrogen, or cyano;

Reply Under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Docket No. 53001AUSM1

- (ii) alkyl, cycloalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aryloxyalkyl, alkenyl, cycloalkylalkyl, heterocyclalkyl, aryl, or arylalkyl, any of which may be optionally independently substituted with one to three halogen, alkoxy, hydroxy, alkyl, or haloalkyl; or
- (iii) $-(CR^{20}R^{21})_m-C(=O)R^{15}$, $-(CR^{20}R^{21})_m-C(=O)OR^{15}$, $-(CR^{20}R^{21})_m-SO_2R^{15a}$,
 $-(CR^{20}R^{21})_m-C(=O)NR^{16}R^{17}$, $-(CR^{20}R^{21})_m-C(=S)NR^{16}R^{17}$, or
 $-(CR^{20}R^{21})_m-C(=O)NR^{16}-SO_2R^{15b}$;

R^{15} is hydrogen, alkyl, haloalkyl, alkenyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, or aryloxyalkyl;

R^{15a} is hydrogen, alkyl, haloalkyl, alkenyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, or aryloxyalkyl, provided that when m is zero R^{15a} is not hydrogen;

R^{15b} is alkyl, haloalkyl, alkenyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, or aryloxyalkyl;

R^{16} and R^{17} are independently hydrogen, alkyl, cycloalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aryloxyalkyl, alkenyl, cycloalkylalkyl, heterocyclalkyl, aryl, or arylalkyl;

or R^{16} and R^{17} together with the nitrogen atom to which they are bonded may combine to form a heterocyclyl ring;

R^{20} and R^{21} at each occurrence are the same or different and are independently hydrogen or alkyl;

X is O or X;

Z is $-S-$, $-S(O)-$ or $-S(O)_2-$;

p is 1 or 2;


p^* is 0, 1, 2, 3 or 4;

q is 0 or 1; and

m is 0, 1 or 2.

12. (Previously Amended) A compound according to claim 11 which is selected from the group consisting of:

Reply Under 37 CFR 1.116
 Expedited Procedure
 Technology Center 1624
 Docket No. 53001AUSM1



where X and X* are independently O or S.

13. (Previously Amended) A compound according to claim 12 selected from the group consisting of:

- 4-[[[4-(7-Chloro-4-quinolinyl)-1-piperazinyl]carbonyl]amino]hexahydro-1H-azepine-1-carboxylic acid, 1,1-dimethylethyl ester;
- 4-[[[4-(7-Chloro-4-quinolinyl)-1-piperazinyl]carbonyl]amino]hexahydro-1H-azepine-1-carboxylic acid, methyl ester;
- 4-[[[4-(7-Chloro-4-quinolinyl)-1-piperazinyl]carbonyl]amino]hexahydro-1H-azepine-1-carboxylic acid, methyl ester;
- 4-[[[4-(7-Chloro-4-quinolinyl)-1-piperazinyl]carbonyl]amino]hexahydro-1H-azepine-1-carboxylic acid, phenylmethyl ester;
- 4-(7-Chloro-4-quinolinyl)-N-[(3*R*)-hexahydro-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;
- 4-(7-Chloro-4-quinolinyl)-N-[(3*S*)-hexahydro-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

Reply Under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Docket No. 53001AUSM1

4-(7-Chloro-4-quinoliny)-N-[(3S)-hexahydro-1-methyl-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;
4-(7-Chloro-4-quinoliny)-N-[(3S)-hexahydro-2-oxo-1-(phenylmethyl)-1*H*-azepin-3-yl]-1-piperazinecarboxamide;
4-(7-Chloro-4-quinoliny)-N-[(3S)-1-[(4-fluorophenyl)methyl]hexahydro-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;
4-(7-Chloro-4-quinoliny)-N-[(3S)-1-ethylhexahydro-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;
(3S)-[[4-(7-Chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-1*H*-azepine-1-acetamide;
4-(7-Chloro-4-quinoliny)-N-[(3S)-hexahydro-2-oxo-1-(3-pyridinylmethyl)-1*H*-azepin-3-yl]-1-piperazinecarboxamide;
4-(7-Chloro-4-quinoliny)-N-[(3S)-hexahydro-2-oxo-1-(2-propenyl)-1*H*-azepin-3-yl]-1-piperazinecarboxamide;
4-(7-Chloro-4-quinoliny)-N-[(3S)-1-(cyclopropylmethyl)hexahydro-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;
4-(7-Chloro-4-quinoliny)-N-[(3S)-hexahydro-1-[(4-methoxyphenyl)methyl]-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;
(3S)-[[4-(7-Chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-1*H*-azepine-1-acetic acid, ethyl ester;
4-(7-Chloro-4-quinoliny)-N-[(3S)-hexahydro-1-[3-(4-morpholinyl)propyl]-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;
4-(2-Amino-7-chloro-4-quinoliny)-N-[(6*R*)-hexahydro-5-oxo-1,4-thiazepin-6-yl]-1-piperazinecarbothioamide;
4-(2-Amino-7-chloro-4-quinoliny)-N-[(6*R*)-hexahydro-5-oxo-1,4-thiazepin-6-yl]-1-piperazinecarboxamide;
4-(2-Amino-7-chloro-4-quinoliny)-N-[(6*R*)-hexahydro-1,1-dioxido-5-oxo-1,4-thiazepin-6-yl]-1-piperazinecarboxamide;
4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-2-oxopyrrolidinyl]-1-piperazinecarboxamide;
4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-2,3,4,5-tetrahydro-2-oxo-1*H*-1-benzazepin-3-yl]-1-piperazinecarboxamide;
4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-2,3,4,5-tetrahydro-1-methyl-2-oxo-1*H*-1-benzazepin-3-yl]-1-piperazinecarboxamide;

Reply Under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Docket No. 53001AUSM1

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-1,2,3,4-tetrahydro-2-oxoquinoliny]-1-piperazinecarboxamide;
4-(2-Amino-7-chloro-4-quinoliny)-N-[(3R)-hexahydro-2-thioxo-1H-azepin-3-yl]-1-piperazinecarboxamide;
4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-1-acetylhexahydro-1H-azepin-3-yl]-1-piperazinecarboxamide;
4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-hexahydro-2-oxo-1H-azepin-3-yl]-1-piperazinecarboxamide;
4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-hexahydro-1-methyl-2-oxo-1H-azepin-3-yl]-1-piperazinecarboxamide;
4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-1-(cyclopropylmethyl)hexahydro-2-oxo-1H-azepin-3-yl]-1-piperazinecarboxamide;
4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-hexahydro-2-oxo-1-(phenylmethyl)-1H-azepin-3-yl]-1-piperazinecarboxamide;
4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-1-[(2,6-dimethylphenyl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-1-piperazinecarboxamide;
4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-hexahydro-2-oxo-1-(2-pyridinylmethyl)-1H-azepin-3-yl]-1-piperazinecarboxamide;
4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-hexahydro-2-oxo-1-(3-pyridinylmethyl)-1H-azepin-3-yl]-1-piperazinecarboxamide;
4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-hexahydro-2-oxo-1-(4-pyridinylmethyl)-1H-azepin-3-yl]-1-piperazinecarboxamide;
4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-hexahydro-1-(2-hydroxy-3-phenoxypropyl)-2-oxo-1H-azepin-3-yl]-1-piperazinecarboxamide;
4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-hexahydro-1-(2-hydroxypropyl)-2-oxo-1H-azepin-3-yl]-1-piperazinecarboxamide;
(3S)-[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-1H-azepine-1-acetic acid, methyl ester;
(3S)-[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-1H-azepine-1-acetic acid;
(3S)-[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-N-(phenylmethyl)-1H-azepine-1-acetamide;

**Reply Under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Docket No. 53001AU\$M1**

(3S)-[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-N-methyl-2-oxo-1*H*-azepine-1-acetamide;

(3S)-[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-N-(4-pyridinyl)-1*H*-azepine-1-acetamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3*R*)-1-(4-fluorophenyl)hexahydro-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

4-[7-Chloro-2-(methylamino)-4-quinoliny]-N-[(3*S*)-hexahydro-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3*S*)-hexahydro-2-oxo-1-(2-phenoxyacetyl)-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

4-(7-Chloro-4-quinoliny)-N-[(3*S*)-1-acetylhexahydro-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3*S*)-1-acetylhexahydro-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3*S*)-1-(cyclopropylcarbonyl)hexahydro-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3*S*)-1-benzoylhexahydro-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3*S*)-1-(ethylsulfonyl)hexahydro-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3*S*)-hexahydro-2-oxo-1-(phenylsulfonyl)-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3*S*)-1-(cyclohexylcarbonyl)hexahydro-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3*S*)-hexahydro-2-oxo-1-[(phenylsulfonyl)amino]carbonyl]-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3*S*)-hexahydro-2-oxo-1-(2-phenylacetyl)-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3*S*)-1-formylhexahydro-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3*S*)-1-(2,2-dimethyl-1-oxopropyl)hexahydro-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

Reply Under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Docket No. 53001AUSM1

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-hexahydro-1-(methylsulfonyl)-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-1*H*-azepine-1-carboxylic acid, methyl ester;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-1*H*-azepine-1-carboxylic acid-ethyl ester;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-1*H*-azepine-1-carboxylic acid,2,2,2-trifluoroethyl ester;

(3S)-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-1*H*-azepine-1-carboxylic acid, 2-propenyl ester;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-1*H*-azepine-1-carboxylic acid phenyl ester;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-1*H*-azepine-1-carboxylic acid-4-fluorophenyl ester;

(3S)-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-1*H*-azepine-1-carboxylic acid, phenylmethyl ester;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-1-cyanohexahydro-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]-N-cyclohexylhexahydro-2-oxo-1*H*-azepine-1-carboxamide;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-1*H*-azepine-1-carboxamide;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-N-(2,2,2-trifluoroethyl)-1*H*-azepine-1-carboxamide;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-1*H*-azepine-1-carboxamide;

(3S)-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-N-propyl-1*H*-azepine-1-carboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-hexahydro-2-oxo-1-(1-pyrrolidinylcarbonyl)-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]-N-cyclopentylhexahydro-2-oxo-1*H*-azepine-1-carboxamide;

Reply Under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Docket No. 53001AUSM1

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]-N-cyclobutylhexahydro-2-oxo-1H-azepine-1-carboxamide;

(3R)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]-N-(4-fluorophenyl)hexahydro-2-oxo-1H-azepine-1-carboxamide;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]-N-ethylhexahydro-2-oxo-1H-azepine-1-carboxamide;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-N-phenyl-1H-azepine-1-carboxamide;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-N-(1-methylethyl)-2-oxo-1H-azepine-1-carboxamide;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]-N-butyhexahydro-2-oxo-1H-azepine-1-carboxamide;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-N-(2-methylpropyl)-2-oxo-1H-azepine-1-carboxamide;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]-N-(1,1-dimethylethyl)hexahydro-2-oxo-1H-azepine-1-carboxamide;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-N,N-dimethyl-2-oxo-1H-azepine-1-carboxamide;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-N-[4-(trifluoromethyl)phenyl]-1H-azepine-1-carboxamide;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]-N-(3-fluorophenyl)hexahydro-2-oxo-1H-azepine-1-carboxamide;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-N-(4-methylphenyl)-2-oxo-1H-azepine-1-carboxamide;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]-N-(2-fluorophenyl)hexahydro-2-oxo-1H-azepine-1-carboxamide;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]-N-(2,6-diethylphenyl)hexahydro-2-oxo-1H-azepine-1-carboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-hexahydro-1-[(methylamino)carbonothioyl]-2-oxo-1H-azepin-3-yl]-1-piperazinecarboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-1-[(ethylamino)carbonothioyl]hexahydro-2-oxo-1H-azepin-3-yl]-1-piperazinecarboxamide;

Reply Under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Docket No. 53001AUSM1

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-hexahydro-1-[(1-methylethyl)amino]carbonothioyl]-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;
4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-hexahydro-2-oxo-1-[(2-propenylamino)carbonothioyl]-1*H*-azepin-3-yl]-1-piperazinecarboxamide;
(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-N-methyl-2-oxo-1*H*-azepine-1-carboxamide;
(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-N-(2-propenyl)-1*H*-azepine-1-carboxamide;
(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]-N-(2-chloroethyl)hexahydro-2-oxo-1*H*-azepine-1-carboxamide; and
(3R)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-N-methyl-2-oxo-1*H*-azepine-1-carboxamide.

14. (Previously Amended) A compound according to claim 13 selected from the group consisting of:

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-hexahydro-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;
4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-1-acetylhexahydro-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;
(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-1*H*-azepine-1-carboxamide;
(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-1*H*-azepine-1-carboxylic acid, methyl ester;
(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]-N-ethylhexahydro-2-oxo-1*H*-azepine-1-carboxamide;
(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-N-methyl-2-oxo-1*H*-azepine-1-carboxamide;
(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]-N-cyclopropylhexahydro-2-oxo-1*H*-azepine-1-carboxamide;
(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-N-(1-methylethyl)-2-oxo-1*H*-azepine-1-carboxamide;
(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-N-(2,2,2-trifluoroethyl)-1*H*-azepine-1-carboxamide; and

Reply Under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Docket No. 53001AUSM1






(3S)-3-[[[4-(2-Amino-7-chloro-4-quinolinyl)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-1H-azepine-1-carboxylic acid-ethyl ester.

15-17. (Canceled)

18. (Original) A pharmaceutical composition comprising at least one compound of claim 11 and a pharmaceutically acceptable vehicle or carrier therefor.

19-22. (canceled)

23. (Previously Presented) A pharmaceutical composition according to claim 18 wherein the compound is selected from the group consisting of:



, and

where X and X* are independently O or S.

**Repty Under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Docket No. 53001AUSM1**

24. (Previously Presented) A pharmaceutical composition according to claim 23 wherein the compound is selected from the group consisting of:

4-[[[4-(7-Chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-1*H*-azepine-1-carboxylic acid, 1,1-dimethylethyl ester;

4-[[[4-(7-Chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-1*H*-azepine-1-carboxylic acid, methyl ester;

4-[[[4-(7-Chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-1*H*-azepine-1-carboxylic acid, methyl ester;

4-[[[4-(7-Chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-1*H*-azepine-1-carboxylic acid, phenylmethyl ester;

4-(7-Chloro-4-quinoliny)-*N*-[(3*R*)-hexahydro-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

4-(7-Chloro-4-quinoliny)-*N*-[(3*S*)-hexahydro-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

4-(7-Chloro-4-quinoliny)-*N*-[(3*S*)-hexahydro-1-methyl-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

4-(7-Chloro-4-quinoliny)-*N*-[(3*S*)-hexahydro-2-oxo-1-(phenylmethyl)-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

4-(7-Chloro-4-quinoliny)-*N*-[(3*S*)-1-[(4-fluorophenyl)methyl]hexahydro-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

4-(7-Chloro-4-quinoliny)-*N*-[(3*S*)-1-ethylhexahydro-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

(3*S*)-[[4-(7-Chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-1*H*-azepine-1-acetamide;

4-(7-Chloro-4-quinoliny)-*N*-[(3*S*)-hexahydro-2-oxo-1-(3-pyridinylmethyl)-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

4-(7-Chloro-4-quinoliny)-*N*-[(3*S*)-hexahydro-2-oxo-1-(2-propenyl)-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

4-(7-Chloro-4-quinoliny)-*N*-[(3*S*)-1-(cyclopropylmethyl)hexahydro-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

4-(7-Chloro-4-quinoliny)-*N*-[(3*S*)-hexahydro-1-[(4-methoxyphenyl)methyl]-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

(3*S*)-[[4-(7-Chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-1*H*-azepine-1-acetic acid, ethyl ester;

Reply Under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Docket No. 53001AUSM1

4-(7-Chloro-4-quinoliny)-N-[(3S)-hexahydro-1-[3-(4-morpholiny)propyl]-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(6*R*)-hexahydro-5-oxo-1,4-thiazepin-6-yl]-1-piperazinecarbothioamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(6*R*)-hexahydro-5-oxo-1,4-thiazepin-6-yl]-1-piperazinecarboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(6*R*)-hexahydro-1,1-dioxido-5-oxo-1,4-thiazepin-6-yl]-1-piperazinecarboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3*S*)-2-oxopyrrolidiny]-1-piperazinecarboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3*S*)-2,3,4,5-tetrahydro-2-oxo-1*H*-1-benzazepin-3-yl]-1-piperazinecarboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3*S*)-2,3,4,5-tetrahydro-1-methyl-2-oxo-1*H*-1-benzazepin-3-yl]-1-piperazinecarboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3*S*)-1,2,3,4-tetrahydro-2-oxoquinoliny]-1-piperazinecarboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3*R*)-hexahydro-2-thioxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3*S*)-1-acetylhexahydro-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3*S*)-hexahydro-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3*S*)-hexahydro-1-methyl-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3*S*)-1-(cyclopropylmethyl)hexahydro-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3*S*)-hexahydro-2-oxo-1-(phenylmethyl)-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3*S*)-1-[(2,6-dimethylphenyl)methyl]hexahydro-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3*S*)-hexahydro-2-oxo-1-(2-pyridinylmethyl)-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3*S*)-hexahydro-2-oxo-1-(3-pyridinylmethyl)-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

Reply Under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Docket No. 53001AUSM1

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-hexahydro-2-oxo-1-(4-pyridinyimethyl)-1H-azepin-3-yl]-1-piperazinecarboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-hexahydro-1-(2-hydroxy-3-phenoxypropyl)-2-oxo-1H-azepin-3-yl]-1-piperazinecarboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-hexahydro-1-(2-hydroxypropyl)-2-oxo-1H-azepin-3-yl]-1-piperazinecarboxamide;

(3S)-[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-1H-azepine-1-acetic acid, methyl ester;

(3S)-[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-1H-azepine-1-acetic acid;

(3S)-[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-N-(phenylmethyl)-1H-azepine-1-acetamide;

(3S)-[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-N-methyl-2-oxo-1H-azepine-1-acetamide;

(3S)-[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-N-(4-pyridinyl)-1H-azepine-1-acetamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3R)-1-(4-fluorophenyl)hexahydro-2-oxo-1H-azepin-3-yl]-1-piperazinecarboxamide;

4-[7-Chloro-2-(methylamino)-4-quinoliny]-N-[(3S)-hexahydro-2-oxo-1H-azepin-3-yl]-1-piperazinecarboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-hexahydro-2-oxo-1-(2-phenoxyacetyl)-1H-azepin-3-yl]-1-piperazinecarboxamide;

4-(7-Chloro-4-quinoliny)-N-[(3S)-1-acetylhexahydro-2-oxo-1H-azepin-3-yl]-1-piperazinecarboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-1-acetylhexahydro-2-oxo-1H-azepin-3-yl]-1-piperazinecarboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-1-(cyclopropylcarbonyl)hexahydro-2-oxo-1H-azepin-3-yl]-1-piperazinecarboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-1-benzoylhexahydro-2-oxo-1H-azepin-3-yl]-1-piperazinecarboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-1-(ethylsulfonyl)hexahydro-2-oxo-1H-azepin-3-yl]-1-piperazinecarboxamide;

**Reply Under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Docket No. 53001AUSM1**

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-hexahydro-2-oxo-1-(phenylsulfonyl)-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-1-(cyclohexylcarbonyl)hexahydro-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-hexahydro-2-oxo-1-[(phenylsulfonyl)amino]carbonyl]-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-hexahydro-2-oxo-1-(2-phenylacetyl)-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-1-formylhexahydro-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-1-(2,2-dimethyl-1-oxopropyl)hexahydro-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-hexahydro-1-(methylsulfonyl)-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

(3S)-3-[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-1*H*-azepine-1-carboxylic acid, methyl ester;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-1*H*-azepine-1-carboxylic acid-ethyl ester;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-1*H*-azepine-1-carboxylic acid,2,2,2-trifluoroethyl ester;

(3S)-[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-1*H*-azepine-1-carboxylic acid, 2-propenyl ester;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-1*H*-azepine-1-carboxylic acid phenyl ester;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-1*H*-azepine-1-carboxylic acid-4-fluorophenyl ester;

(3S)-[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-1*H*-azepine-1-carboxylic acid, phenylmethyl ester;

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-1-cyanohexahydro-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]-N-cyclohexylhexahydro-2-oxo-1*H*-azepine-1-carboxamide;

Reply Under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Docket No. 53001AUSM1

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-1*H*-azepine-1-carboxamide;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-*N*-(2,2,2-trifluoroethyl)-1*H*-azepine-1-carboxamide;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]-*N*-cyclopropylhexahydro-2-oxo-1*H*-azepine-1-carboxamide;

(3S)-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-*N*-propyl-1*H*-azepine-1-carboxamide;

4-(2-Amino-7-chloro-4-quinoliny)-*N*-[(3S)-hexahydro-2-oxo-1-(1-pyrrolidinylcarbonyl)-1*H*-azepin-3-yl]-1-piperazinecarboxamide;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]-*N*-cyclopentylhexahydro-2-oxo-1*H*-azepine-1-carboxamide;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]-*N*-cyclobutylhexahydro-2-oxo-1*H*-azepine-1-carboxamide;

(3R)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]-*N*-(4-fluorophenyl)hexahydro-2-oxo-1*H*-azepine-1-carboxamide;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]-*N*-ethylhexahydro-2-oxo-1*H*-azepine-1-carboxamide;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-*N*-phenyl-1*H*-azepine-1-carboxamide;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-*N*-(1-methylethyl)-2-oxo-1*H*-azepine-1-carboxamide;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]-*N*-butylhexahydro-2-oxo-1*H*-azepine-1-carboxamide;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-*N*-(2-methylpropyl)-2-oxo-1*H*-azepine-1-carboxamide;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]-*N*-(1,1-dimethylethyl)hexahydro-2-oxo-1*H*-azepine-1-carboxamide;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-*N,N*-dimethyl-2-oxo-1*H*-azepine-1-carboxamide;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-*N*-(trifluoromethyl)phenyl-1*H*-azepine-1-carboxamide;

**Reply Under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Docket No. 53001AUSM1**

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]-N-(3-fluorophenyl)hexahydro-2-oxo-1*H*-azepine-1-carboxamide;
(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-N-(4-methylphenyl)-2-oxo-1*H*-azepine-1-carboxamide;
(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]-N-(2-fluorophenyl)hexahydro-2-oxo-1*H*-azepine-1-carboxamide;
(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]-N-(2,6-diethylphenyl)hexahydro-2-oxo-1*H*-azepine-1-carboxamide;
4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-hexahydro-1-[(methylamino)carbonothioyl]-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;
4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-1-[(ethylamino)carbonothioyl]hexahydro-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;
4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-hexahydro-1-[(1-methylethyl)amino]carbonothioyl]-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;
4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-hexahydro-2-oxo-1-[(2-propenylamino)carbonothioyl]-1*H*-azepin-3-yl]-1-piperazinecarboxamide;
(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-N-methyl-2-oxo-1*H*-azepine-1-carboxamide;
(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-N-(2-propenyl)-1*H*-azepine-1-carboxamide;
(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]-N-(2-chloroethyl)hexahydro-2-oxo-1*H*-azepine-1-carboxamide; and
(3R)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-N-methyl-2-oxo-1*H*-azepine-1-carboxamide.

25. (Previously Presented) A pharmaceutical composition according to claim 24 wherein the compound is selected from the group consisting of:

4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-hexahydro-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;
4-(2-Amino-7-chloro-4-quinoliny)-N-[(3S)-1-acetylhexahydro-2-oxo-1*H*-azepin-3-yl]-1-piperazinecarboxamide;
(3S)-3-[[[4-(2-Amino-7-chloro-4-quinoliny)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-1*H*-azepine-1-carboxamide;

**Reply Under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Docket No. 53001AUSM1**

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinolinyl)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-1*H*-azepine-1-carboxylic acid, methyl ester;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinolinyl)-1-piperazinyl]carbonyl]amino]-*N*-ethylhexahydro-2-oxo-1*H*-azepine-1-carboxamide;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinolinyl)-1-piperazinyl]carbonyl]amino]hexahydro-*N*-methyl-2-oxo-1*H*-azepine-1-carboxamide;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinolinyl)-1-piperazinyl]carbonyl]amino]-*N*-cyclopropylhexahydro-2-oxo-1*H*-azepine-1-carboxamide;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinolinyl)-1-piperazinyl]carbonyl]amino]hexahydro-*N*-(1-methylethyl)-2-oxo-1*H*-azepine-1-carboxamide;

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinolinyl)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-*N*-(2,2,2-trifluoroethyl)-1*H*-azepine-1-carboxamide; and

(3S)-3-[[[4-(2-Amino-7-chloro-4-quinolinyl)-1-piperazinyl]carbonyl]amino]hexahydro-2-oxo-1*H*-azepine-1-carboxylic acid-ethyl ester.